Esperion Therapeutics Analyst Ratings
BenzingaApr 10 06:47 ET
Northland Securities Sticks to Their Hold Rating for Esperion (ESPR)
TipRanksMar 25 08:55 ET
Esperion Therapeutics Analyst Ratings
BenzingaMar 25 07:33 ET
Esperion Therapeutics Analyst Ratings
BenzingaFeb 27 14:46 ET
Esperion Therapeutics Analyst Ratings
BenzingaNov 20, 2023 08:25 ET
Esperion Therapeutics Analyst Ratings
BenzingaNov 13, 2023 11:17 ET
Needham Maintains Buy on Esperion Therapeutics, Lowers Price Target to $8
BenzingaNov 7, 2023 15:29 ET
Esperion Therapeutics Analyst Ratings
BenzingaNov 7, 2023 15:28 ET
Needham Reiterates Buy on Esperion Therapeutics, Maintains $9 Price Target
BenzingaOct 2, 2023 06:31 ET
Esperion Therapeutics Analyst Ratings
BenzingaOct 2, 2023 06:29 ET
HC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $22 Price Target
BenzingaAug 28, 2023 06:41 ET
Esperion Therapeutics Analyst Ratings
BenzingaAug 28, 2023 06:38 ET
Needham Maintains Buy on Esperion Therapeutics, Lowers Price Target to $9
BenzingaAug 2, 2023 04:11 ET
Esperion Therapeutics Analyst Ratings
BenzingaAug 2, 2023 04:10 ET
Northland Securities Upgrades Esperion Therapeutics to Market Perform From Underperform, Raises Price Target to $2 From $1
MT NewswiresAug 1, 2023 13:57 ET
Esperion Jumps 15% as BofA Double-upgrades Citing Near-term Upside
Seeking AlphaJun 15, 2023 09:12 ET
B of A Securities Upgrades Esperion Therapeutics to Buy, Raises Price Target to $4
BenzingaJun 15, 2023 06:21 ET
Analyst Ratings for Esperion Therapeutics
BenzingaJun 1, 2023 15:02 ET
HC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $22 Price Target
BenzingaJun 1, 2023 10:35 ET
Needham Maintains Buy on Esperion Therapeutics, Lowers Price Target to $10
BenzingaMay 9, 2023 12:27 ET
No Data
No Data